Title
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis

Permalink
https://escholarship.org/uc/item/1m59v1hk

Journal
Annals of Allergy Asthma & Immunology, 95(6)

ISSN
1081-1206

Authors
Meltzer, E O
Hampel, F C
Ratner, P H
et al.

Publication Date
2005-12-01

Peer reviewed
Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis

Eli O. Meltzer, MD; Frank C. Hampel, MD; Paul H. Ratner, MD; David I. Bernstein, MD; Lawrence V. Larsen, MD; William E. Berger, MD; Albert F. Finn, Jr, MD; Bradley F. Marple, MD; Peter S. Roland, MD; G. Michael Wall, PhD; Michael J. Brubaker, PhD; Carolyn Dimas, BSN; Susan L. Potts, MS; Lewis H. Silver, PhD; and J. Rod Barnes, MBA

INTRODUCTION

Olopatadine hydrochloride is being developed in a nasal spray formulation for the treatment of seasonal allergic rhinitis (SAR). This disease is an allergen-induced inflammatory response, with an estimated incidence of 10% and 30% in the general population. On exposure to a specific antigen, allergic patients exhibit a hypersensitivity response that may take minutes, or even days, to manifest. Signs and symptoms associated with SAR include sneezing, nasal congestion, rhinorrhea, ocular itching and watering, paranasal pressure, and fatigue.

Olopatadine is an antiallergy agent that inhibits mast cell mediator release and possesses histamine H1 receptor antagonist activity. An ophthalmic formulation of 0.1% olopatadine solution is approved in the United States and Canada as Patanol and in Europe as Opatanol (both from Alcon Research Ltd, Fort Worth, TX) for treating the signs and symptoms of allergic conjunctivitis. The ocular pharmacology of olopatadine has been extensively reviewed. An oral form, 2.5- and 5-mg tablets, has been approved as Allelock (Kyowa Hakko Co Ltd, Tokyo, Japan) in Japan for the treatment of allergic rhinitis, chronic urticaria, atopic dermatitis, prurigo, cutaneous pruritus, psoriasis vulgaris, and erythema exudativum multiforme. The pharmacokinetics, pharmacology, and clinical trials of the oral dosage have also been reviewed. Olopatadine (10 mg/kg by mouth) has also been shown to inhibit the nasal symptoms of allergic rhinitis in sensitized guinea pigs by inhibiting the release of histamine and possibly peptide leukotrienes into the nasal cavity.
This article describes the first multicenter clinical trial designed to evaluate the safety and efficacy of 0.4% and 0.6% olopatadine in the form of a nasal spray (443 and 665 µg, respectively, of olopatadine hydrochloride per spray) vs placebo spray in the treatment of patients with SAR.

**MATERIALS AND METHODS**

**Patients**

Enrolled patients were 12 years or older with a history of SAR for at least the preceding 2 years. All the patients demonstrated allergic sensitivity to a prevalent fall allergen as defined by a positive reaction on skin prick testing (a wheal size ≥3 mm greater than the diluent) or intradermal testing (a wheal size ≥7 mm greater than the diluent). The study protocol was approved by an institutional review board, and an informed consent document was signed by all the patients before participation in the study. Women of childbearing potential were enrolled if they agreed to use an acceptable method of contraception. Patients who had aberrant nasal anatomy, abnormal presubject study test results, severe obstructing congestion, recent sinusitis, or abnormal 12-lead electrocardiographic or other abnormal cardiovascular values were excluded from study participation. Medication washout times were 30 days for systemic, inhaled, and ocular corticosteroids; 14 days for intranasal corticosteroids, systemic antibiotics and antihistamines, leukotriene inhibitors, anticholinergic agents, and systemic antibiotics; 7 days for ocular antiallergy agents; 3 days for oral decongestants and nonsteroidal anti-inflammatory agents; and 1 day for nasal and ocular saline. Patients who had undergone previous immunotherapy were required to be stable for 30 days before and throughout the trial.

**Study Design**

This was a 2-week, multicenter (33 sites across the United States), randomized, double-blind, parallel-group, placebo-controlled, 3-armed study of 2 concentrations of olopatadine nasal spray and a placebo spray conducted between August 19 and November 27, 2002. Beginning with the placebo run-in period and continuing to the study exit, patients recorded in a diary the symptom severity of their itchy nose, runny nose, stuffy nose, sneezing, itchy eyes, and watery eyes using a 4-point scale (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The sum of scores for the 4 nasal symptoms was defined as the total nasal symptom score (TNSS). Patients evaluated their symptoms as experienced at that moment (instantaneous) and in the hours since the last dose of study medication was taken (reflective), in the morning before any other activity, and at bedtime. Each patient also completed the allergy-specific Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in the treatment randomization and exit visits.

During the single-blind placebo spray run-in period, patients had to have a minimum reflective TNSS of 36 of a possible 72 points on 3 of the 4 days prior to randomization to qualify for the double-blind treatment phase of the study. Patients were then randomized to receive 1 of 3 treatment regimens: two 100-µL sprays per nostril twice daily of 0.4% olopatadine nasal spray (total daily dose of 3.2 mg), 0.6% olopatadine nasal spray (total daily dose of 4.8 mg), or placebo (vehicle containing benzalkonium chloride, phosphates, edetate, povidone, sodium chloride, and water but no active ingredient) nasal spray (Alcon Research Ltd). After a week of study treatment, each patient was contacted by telephone to check protocol compliance, medication changes, potential adverse events, and diary completion. Patients returned after 2 weeks of double-blind therapy for an exit visit that included a physical examination, measurement of vital signs, laboratory analyses, completion of the RQLQ, and collection of diaries.

**Statistical Methods**

The primary statistical objective of this study was to demonstrate the statistical superiority of 0.4% and 0.6% olopatadine nasal sprays relative to placebo in the treatment of allergic rhinitis as evidenced by the percentage change from baseline in the TNSS. A Dunnett t test was used to compare changes from baseline between the olopatadine treatments and placebo for the primary and each of the secondary variables. This procedure was designed to test multiple treatments against a single control and, therefore, preserved statistical power in the presence of multiplicity.

Primary and secondary conclusions were based on the intent-to-treat data set. Based on similar studies in the literature, a treatment difference of 12.5% in the TNSS change from baseline was assumed, with an approximated SD of 42%. With a projected 240 evaluable patients per group (N = 720), this study was predicted to have 90% power to detect a significant treatment difference between the olopatadine nasal sprays and placebo. All statistical tests were 2-sided, with α = .05.

**Efficacy.** The primary efficacy variable was the percentage change from baseline in the reflective TNSS, defined as the average of the morning and bedtime reflective severity scores for the sum of the patients’ assessments of runny nose, stuffy nose, itchy nose, and sneezing (averaged across all days). Secondary efficacy variables included the percentage change from baseline in the instantaneous TNSS, individual symptoms (ie, runny nose, itchy nose, sneezing, stuffy nose, watery eyes, and itchy eyes), and quality of life (QoL). Percentage change from baseline in the instantaneous TNSS was defined as the average of the morning and bedtime instantaneous (how the patient felt at that time) severity scores for the sum of the patients’ assessments of symptoms (averaged across all days). All baseline scores were calculated using the appropriate measurements from the 3 highest days of the 4 days before randomization. These 3 days were chosen by calculating the average (mean of the awakening and bedtime assessments) for a given reflective or instantaneous symptom (TNSS or individual symptoms) for each day. The QoL was evaluated using the validated 28-item RQLQ (overall and by domain) of Juniper and Guyatt. To minimize possible bias
from early dropouts, efficacy variables were based on an intent-to-treat approach that included all patients with at least 1 postbaseline observation regardless of the length of therapy. An overall analysis was based on the mean change for each patient using available data and carrying that data forward.

Safety. A total of 845 patients were given placebo during a 3- to 21-day run-in period; 280 patients did not qualify for randomization. The remaining 565 patients were randomized: 184 (32.6%) received 0.6% olopatadine, 189 (33.5%) received 0.4% olopatadine, and 192 (34.0%) received placebo. Of 845 enrolled patients, 565 met the study criteria, were randomized to treatment, and were evaluable for the safety and intent-to-treat analyses. All the data presented in this article are from the intent-to-treat data set. The 3 treatment groups were similar in terms of demographic characteristics (Table 1). The average age was 35 years (range, 12–80 years). Males composed 38.2% of the patient group; 75.6% of the patients were white, 11.5% were African American, 1.1% were Asian, 10.6% were Hispanic, and 1.2% were of other races.

Primary Efficacy: Reflective TNSS

The 0.4% and 0.6% olopatadine treatments were statistically superior to placebo use for the mean change from baseline of the overall reflective TNSS (P = .004 and P < .001, respectively) (Table 2). The average percentage reduction in TNSS from baseline was 39.2% for patients who received 0.6% olopatadine, 35.8% for patients who received 0.4% olopatadine, and 27.0% for patients who received placebo.

Secondary Efficacy

Reflective assessments of individual symptoms. The 0.4% and 0.6% olopatadine treatments were statistically superior to placebo use in reducing the reflective evaluation of the severity of runny nose (P = .046 and P < .001, respectively), itchy nose (P = .005 and P = .001, respectively), and sneezing (P < .001 for both concentrations) (Table 2). Although the 0.4% and 0.6% olopatadine treatments were numerically more effective than placebo use (25.7% and 24.5% decrease, respectively, vs 22.0% for placebo) for the reflective evaluation of severity for stuffy nose, the differences were not statistically significant (P = .70 and P = .85, respectively) (Table 2). The 0.4% and 0.6% olopatadine treatments were also numerically superior to placebo use in reflective severity of itchy eyes (35.2% and 41.4% decreases, respectively, vs 30.2% for placebo) and watery eyes (44.3% and 46.7% decreases, respectively, vs 37.1% for placebo), but only the 0.6% treatment reached statistical superiority for itchy eyes (P = .02) (Table 2).

TNSS during the 2-week period by day. For each of the 14 days of treatment, 0.6% olopatadine was significantly superior to placebo for percentage change from baseline in reflect-
tive TNSS ($P < .05$); the $0.4\%$ treatment reached significance ($P < .05$) for most days (Fig 1).

**Instantaneous evaluation of the overall TNSS and individual symptoms.** The $0.4\%$ and $0.6\%$ olopatadine treatments were statistically superior to placebo use for the percentage change from baseline in the overall instantaneous TNSS ($P = .02$ and $P = .003$, respectively) (Table 3). By instantaneous evaluation, $0.6\%$ olopatadine treatment was significantly superior to placebo use for runny nose ($P = .009$), itchy nose ($P = .02$), sneezing ($P < .001$), itchy eyes ($P = .008$), and watery eyes ($P = .02$) but not for stuffy nose ($P = .32$) (Table 3). The $0.4\%$ olopatadine treatment improvement was generally less than that noted for $0.6\%$ olopatadine treatment; however, it was superior to placebo for instantaneous evaluation of all symptoms except stuffy nose ($P = .69$) and ocular symptoms ($P = .31$ for itchy eyes and $P = .44$ for watery eyes) (Table 3).

**Quality of life.** The $0.4\%$ and $0.6\%$ olopatadine treatments improved the overall RQLQ score from baseline significantly greater than placebo ($P = .02$ and $P < .001$, respectively) (Fig 2). The $0.6\%$ olopatadine treatment was superior to placebo for all 7 domains: activities ($P < .001$), sleep ($P < .001$), non-nose/eye symptoms ($P = .004$), practical problems ($P < .001$), nasal symptoms ($P = .02$), and emotional aspects ($P = .001$). The $0.4\%$ olopatadine treatment was superior to placebo for 4 of the 7 domains ($P < .05$) but did not reach significance on the sleep ($P = .13$), non-nose/eye symptoms ($P = .08$), and emotional ($P = .16$) subscales.

**Safety Results**
No serious adverse events, related or unrelated to therapy, were reported during the study. Nonserious adverse events in the overall safety populations were usually mild to moderate.

---

**Table 3. Percentage Change From Baseline in the Instantaneous Assessments of Symptoms of Seasonal Allergic Rhinitis**

<table>
<thead>
<tr>
<th>Variable</th>
<th>0.6% Olopatadine group</th>
<th>0.4% Olopatadine group</th>
<th>Placebo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNSS</td>
<td>$-33.3 \pm 27.9$</td>
<td>$-31.6 \pm 27.6$</td>
<td>$-23.6 \pm 32.0$</td>
</tr>
<tr>
<td>Runny nose</td>
<td>$-32.5 \pm 34.2$</td>
<td>$-30.2 \pm 34.3$</td>
<td>$-14.9 \pm 90.7$</td>
</tr>
<tr>
<td>Stuffy nose</td>
<td>$-22.7 \pm 33.9$</td>
<td>$-20.7 \pm 29.2$</td>
<td>$-18.4 \pm 31.5$</td>
</tr>
<tr>
<td>Itchy nose</td>
<td>$-34.2 \pm 33.6$</td>
<td>$-33.8 \pm 34.9$</td>
<td>$-24.0 \pm 43.8$</td>
</tr>
<tr>
<td>Sneezing</td>
<td>$-46.4 \pm 46.7$</td>
<td>$-45.7 \pm 41.8$</td>
<td>$-23.5 \pm 77.2$</td>
</tr>
<tr>
<td>Itchy eyes</td>
<td>$-39.4 \pm 36.2$</td>
<td>$-32.8 \pm 41.0$</td>
<td>$-27.2 \pm 43.7$</td>
</tr>
<tr>
<td>Watery eyes</td>
<td>$-44.0 \pm 42.2$</td>
<td>$-37.6 \pm 43.9$</td>
<td>$-32.5 \pm 42.8$</td>
</tr>
</tbody>
</table>

Abbreviation: TNSS, total nasal symptom score.

* Data are given as mean ± SD.
† The 0.6% olopatadine group vs the placebo group.
‡ The 0.4% olopatadine group vs the placebo group.
usually resolved with or without treatment, and generally did not interrupt patient continuation in the study. Eleven patients discontinued the treatment phase of the study owing to adverse events (Table 4). Causality assessments revealed that only 4 of 11 of these patients' adverse events were related to therapy. No safety issues were identified and no treatment-related changes were observed in the laboratory test results of hematology, blood chemistry, and urinalysis. The evaluation of cardiovascular variables showed that olopatadine nasal spray administered twice daily was safe and well tolerated. There also were no clinically relevant mean or individual changes in physical (including nasal) examinations for any of the treatment arms during this study. The most common adverse event was bitter taste, and it seemed to be dose related (Table 5). The incidence of somnolence was negligible (0.5% for 0.4% and 0.6% olopatadine and 0% for placebo) (Table 5).

**DISCUSSION**

In this study, treatment with 0.4% and 0.6% olopatadine, 2 sprays per nostril twice daily, provided significant relief from allergy symptoms compared with placebo spray during the 2-week trial. In this clinical trial, the TNSS was defined as a combination score for the 4 major symptoms of allergic rhinitis: sneezing, runny nose, itchy nose, and stuffy nose. Use of the TNSS as the primary efficacy variable is appropriate for an allergic rhinitis study with the goal of assessing a medication’s overall impact on the rhinitis symptoms.

---

Table 4. Summary of 11 Patients Who Discontinued During the Randomized Treatment Phase Because of Nonserious Adverse Events

<table>
<thead>
<tr>
<th>Patient age, y</th>
<th>Treatment</th>
<th>Coded adverse event</th>
<th>Outcome of event</th>
<th>CA</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>0.6% Olopatadine</td>
<td>Headache</td>
<td>Resolved w/Tx</td>
<td>R</td>
</tr>
<tr>
<td>57</td>
<td>0.6% Olopatadine</td>
<td>Sinusitis</td>
<td>Resolved w/Tx</td>
<td>R</td>
</tr>
<tr>
<td>33</td>
<td>0.6% Olopatadine</td>
<td>Pneumonia</td>
<td>Resolved w/Tx</td>
<td>NR</td>
</tr>
<tr>
<td>36</td>
<td>0.4% Olopatadine</td>
<td>Dizziness</td>
<td>Resolved wo/Tx</td>
<td>R</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dyspepsia</td>
<td>Resolved wo/Tx</td>
<td>R</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Headache</td>
<td>Resolved wo/Tx</td>
<td>R</td>
</tr>
<tr>
<td>33</td>
<td>0.4% Olopatadine</td>
<td>Pharyngitis</td>
<td>Resolved w/Tx</td>
<td>NR</td>
</tr>
<tr>
<td>27</td>
<td>0.4% Olopatadine</td>
<td>Bronchitis</td>
<td>Resolved w/Tx</td>
<td>NR</td>
</tr>
<tr>
<td>40</td>
<td>0.4% Olopatadine</td>
<td>Infection</td>
<td>Resolved w/Tx</td>
<td>NR</td>
</tr>
<tr>
<td>50</td>
<td>0.4% Olopatadine</td>
<td>Dermatitis lichen</td>
<td>Resolved w/Tx</td>
<td>NR</td>
</tr>
<tr>
<td>30</td>
<td>0.4% Olopatadine</td>
<td>Sinusitis</td>
<td>Resolved w/Tx</td>
<td>NR</td>
</tr>
<tr>
<td>14</td>
<td>Placebo</td>
<td>Headache</td>
<td>Resolved wo/Tx</td>
<td>R</td>
</tr>
<tr>
<td>22</td>
<td>Placebo</td>
<td>Bronchitis</td>
<td>Lost to follow-up</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nausea</td>
<td>Resolved wo/Tx</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vomiting</td>
<td>Resolved wo/Tx</td>
<td>NR</td>
</tr>
</tbody>
</table>

Abbreviations: CA, causality assessment; NR, not related; R, related; w/Tx, with treatment; wo/Tx, without treatment.
symptoms may have been systemic. Tamura et al observed that olopatadine (2.5- and 5-mg tablets) was significantly greater than placebo therapy for improving TNSSs and each individual symptom score, except stuffy nose. Comparisons of 0.4% olopatadine with placebo also reached statistical significance except for ocular symptoms and 3 RQLQ domains (sleep, non-nose/eye symptoms, and emotional). Although both concentrations of olopatadine were slightly numerically greater than placebo spray for reducing congestion, there were no statistically significant differences. In addition, no patients dropped out of the study because of congestion.

Both concentrations of olopatadine provided numerically greater reductions in ocular symptoms (itchy and watery eyes) vs placebo. The 0.6% olopatadine treatment reached statistical significance for instantaneous and reflective evaluation of itchy eyes and for instantaneous (but not reflective) evaluation of watery eyes. The effect of olopatadine on ocular symptoms may have been systemic. Tamura et al observed that oral administration of 0.1% and 1 mg/kg of olopatadine significantly inhibited passive anaphylaxis reaction–induced vascular hyperpermeability of the conjunctiva in a rat model of allergic conjunctivitis, suggesting a systemic effect on ocular symptoms.

Vehicle nasal spray was used as the placebo. The placebo spray, not surprisingly, produced beneficial effects. It reduced the symptom scores for every variable (Tables 2 and 3) and improved QoL (Fig 2). The placebo response to a nasal spray can be even more confounding than the response to an oral formulation because the nasal spray can possibly clear allergens from nasal passages, thereby reducing the dose of allergen exposure and, hence, the allergic response.

As an additional measure of efficacy, QoL evaluation was also used in this study. Issues of QoL have been used extensively in evaluating the considerable health-related consequences of allergic rhinitis. Use of 0.6% olopatadine significantly improved each of the 7 individual domains during treatment compared with baseline. Treatment with 0.4% olopatadine was superior on 4 domains compared with baseline. Treatment with 0.6% olopatadine was statistically significantly greater than placebo for improving QoL assessments. Both 0.4% and 0.6% olopatadine were well tolerated in this study. These data support the use of olopatadine nasal spray as an effective and safe anti-allergy agent for the treatment of symptoms of allergic rhinitis.

**ACKNOWLEDGMENTS**

We thank Kaye Weber, MS, RRT, and Beverly Loyd for preparation of the manuscript and the other principal study investigators: Dean Atkinson, MD, Oklahoma City, OK; Peter B. Boggs, MD, Shreveport, LA; B. Lauren Charous, MD, Milwaukee, WI; Steven Cohen, MD, West Allis, WI; Terry R. Denison, MD, Shawnee Mission, KS; Linda Ford, MD, Papilion, NE; Sandra Gawchik, DO, Upland, PA; Larry Gilderman, DO, Pembroke Pines, FL; Sherwin Gillman, MD, Orange, CA; Pinkus Goldberg, MD, Indianapolis, IN; Brad Goodman, MD, Savannah, GA; David Gossage, MD, Knoxville, TN; Robert Grubbe, MD, Oxford, AL; Dan Henry, MD, Salt Lake City, UT; Neil Kao, MD, Greenville, SC; Craig LaForce, MD, Raleigh, NC; Richard Lockey, MD, Tampa, FL; Jacob Pinnas, MD, Tuscon, AZ; Kevin Schaffer, MD, Lawrenceville, GA; William Seger, MD, Fort Worth, TX; Tommy Sim, MD, Friendswood, TX; Wayne Sinclair, MD, Missoula, MT; Karl Sitz, MD, Little Rock, AR; George Edward Stewart II, MD, Ocala, FL; and Suzanne Weakley, MD, Houston, TX.

**REFERENCES**

5. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydro-

---

**Table 5. Related Adverse Events by Treatment Group**

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>0.6% Olopatadine group</th>
<th>0.4% Olopatadine group</th>
<th>Placebo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bitter taste</td>
<td>9.2</td>
<td>5.8</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>2.2</td>
<td>2.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>3.8</td>
<td>1.1</td>
<td>1.0</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>1.6</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Somnolence</td>
<td>0.5</td>
<td>0.5</td>
<td>0</td>
</tr>
</tbody>
</table>

* Data are given as percentages.


Requests for reprints should be addressed to:
Eli O. Meltzer, MD
Allergy and Asthma Medical Group and Research Center APC
9610 Granite Ridge Dr
Suite B
San Diego, CA 92123
E-mail: EOMELTZER@aol.com.